Patent Infringement Lawsuits: Defending Pharmaceutical and Tech Inventions in the Philippines
Introduction: patent suits involving pharma and technology disputes
Patent infringement suits in the Philippines often arise when a multinational patent owner claims that a local manufacturer, distributor, or importer copied a patented product or used a patented process without permission. In pharmaceutical and technology disputes, outcomes frequently turn on how the patent claims are read, what technical features are actually covered, and whether the accused product or process matches all elements of the claim. These disputes can carry immediate commercial consequences because a finding of infringement may lead to damages, injunctions, and destruction or disposal of infringing goods.
Governing law: the Intellectual Property Code provisions used in infringement litigation
The principal statute is R.A. No. 8293 (Intellectual Property Code of the Philippines), approved June 6, 1997. For infringement suits, the core provision is Section 76, which defines acts of patent infringement and authorizes a civil action for damages and injunctive relief.
Under R.A. No. 8293, Section 76.1, patent infringement includes the unauthorized making, using, offering for sale, selling, or importing of a patented product, or a product obtained directly or indirectly from a patented process, or the unauthorized use of a patented process. Under Section 76.2, the patentee (or a person with right/title/interest in the invention) may sue to recover damages, attorney’s fees, litigation expenses, and obtain an injunction. When damages cannot be computed with reasonable certainty, Section 76.3 allows the court to award reasonable royalty. The court may also award damages up to three (3) times actual damages in proper cases (Section 76.4), and may order the disposal outside channels of commerce or destruction of infringing goods and implements used predominantly for infringement (Section 76.5).
Direct vs indirect (contributory/inducement) infringement
Philippine law recognizes direct infringement (Section 76.1) and indirect infringement under Section 76.6 (inducement or contributory infringement).
In Tuna Processors, Inc. v. Frescomar Corporation, et al., G.R. No. 226445, 2024, the Supreme Court explained that indirect infringement under Section 76.6 includes (a) inducing another to infringe and (b) contributory infringement (supplying a component especially adapted for infringing, knowing it is for infringement, and not suitable for substantial non-infringing use). The Court also stressed that indirect infringement presupposes direct infringement; there can be no contributory infringement if there is no direct infringement.
The controlling issue in most cases: claim construction (what the patent actually covers)
In pharma and tech disputes, the most important battleground is usually not the marketing story or the product label—it is the patent claim language. The Supreme Court has repeatedly held that patent protection is determined by the claims.
In Phillips Seafood Philippines Corporation v. Tuna Processors, Inc., G.R. No. 214148, 2023, the Court described a two-step approach in infringement determination: (1) interpret the claims to determine the patent’s scope and meaning, and (2) compare the accused product or process against the properly interpreted claims. The Court emphasized that claims serve both a definitional function (defining the scope of protection) and a public notice function (informing the public and courts of the extent of protection).
Consistent with this, Tuna Processors, Inc. v. Frescomar Corporation, et al., G.R. No. 226445, 2024 stressed that the scope of protection is strictly determined by the claims, not by the description or unclaimed features, and that all elements of the claim must be appropriated for infringement to exist.
Infringement tests used by Philippine courts: literal infringement and the doctrine of equivalents
In many disputes, an accused local company will argue that its product/process differs in at least one essential claim element. If the court agrees that an element is missing, literal infringement fails.
Patent owners may then argue infringement under the doctrine of equivalents. However, Philippine jurisprudence applies this doctrine carefully. In Smith Kline Beckman Corporation v. Court of Appeals, et al., G.R. No. 126627, 2003, the Court held that the patentee is bound by the clear and distinct language of the claims and may not claim anything beyond them. The Court also described the equivalence inquiry in functional terms: whether the accused product performs substantially the same function, in substantially the same way, to achieve substantially the same result, and it placed the burden on the patentee to prove equivalence.
In Phillips Seafood Philippines Corporation v. Tuna Processors, Inc., G.R. No. 214148, 2023, the Court reiterated that infringement—literal or by equivalents—requires that all essential elements (or their equivalents) are present, and that the doctrine of equivalents cannot be stretched to erase a material claim element.
What multinational plaintiffs usually allege in pharma and tech suits
In cross-border disputes, multinational companies typically anchor their complaint on one or more of the acts enumerated in R.A. No. 8293, Section 76.1. Common patterns include:
1) Importation-based claims: the local entity imports a product allegedly within the patent claims.
2) Manufacturing-based claims: the local entity makes or uses a process alleged to be within a process patent’s claims.
3) Sales and offer-for-sale claims: the local entity markets the product (including online listings), even if actual manufacturing occurred elsewhere.
4) Indirect infringement allegations: the local entity supplies a component or induces another party to commit direct infringement (Section 76.6), often pleaded against distributors, integrators, or OEM/ODM arrangements.
Defending local entities: the typical defenses that match Philippine doctrine
Because Philippine courts focus on claims and claim elements, defenses are commonly built around non-infringement theories rather than broad business arguments.
The following table summarizes common defense themes and their legal anchor points:
Common defenses in patent infringement cases (summary table)
Defense theme — How it works in court — Primary authority
Non-infringement (missing claim element) — Show that at least one required claim element is not present in the accused product/process; partial overlap is insufficient — Phillips Seafood Philippines Corporation v. Tuna Processors, Inc., G.R. No. 214148, 2023; Tuna Processors, Inc. v. Frescomar Corporation, et al., G.R. No. 226445, 2024
Claim construction limits — Argue that the patentee’s reading expands beyond what was claimed; courts are bound by claim language — Smith Kline Beckman Corporation v. Court of Appeals, et al., G.R. No. 126627, 2003; Tuna Processors, Inc. v. Frescomar Corporation, et al., G.R. No. 226445, 2024
No indirect infringement without direct infringement — If there is no direct infringement, inducement/contributory liability fails — Tuna Processors, Inc. v. Frescomar Corporation, et al., G.R. No. 226445, 2024
Attack on equivalence proof — Require proof of substantially same function/way/result; prevent doctrine of equivalents from deleting an element — Smith Kline Beckman Corporation v. Court of Appeals, et al., G.R. No. 126627, 2003; Phillips Seafood Philippines Corporation v. Tuna Processors, Inc., G.R. No. 214148, 2023
Evidence and case presentation: what usually decides outcomes
Patent cases are evidence-heavy. Even where the legal standards are clear, results often depend on whether the parties can translate technical facts into claim elements that the court can compare against the accused product or process.
In general, parties should be prepared to present:
Claim charts mapping each claim element to the accused product/process (or demonstrating a missing element).
Technical documents such as specifications, batch records (pharma), source code/module descriptions (software-related inventions), engineering drawings, user manuals, and test reports.
Competent technical testimony that supports claim interpretation and element-by-element comparison consistent with the two-step approach described in Phillips Seafood Philippines Corporation v. Tuna Processors, Inc., G.R. No. 214148, 2023.
Remedies and exposure: damages, injunction, and destruction/disposal of goods
For defendants, it is important to understand the remedy package the statute authorizes. Under R.A. No. 8293, Section 76.2, the patentee may recover damages and secure an injunction. If damages are not readily ascertainable, the court may award reasonable royalty (Section 76.3). In appropriate cases, damages may be awarded above actual damages up to three times (Section 76.4). Courts may also order destruction or disposal outside commerce of infringing goods and predominantly used implements (Section 76.5).
For multinational plaintiffs, these remedies support requests for immediate commercial relief. For local entities, early case assessment should consider supply-chain impact, inventory risk, and the litigation cost of technical proof.
Typical scenarios in multinational vs local entity disputes
Scenario A (pharma importation): A local distributor imports a generic product; the patentee alleges the active ingredient formulation or process falls within the patent claims. The defense often focuses on claim construction and showing that at least one element is missing or materially different, consistent with the “all elements” requirement discussed in Tuna Processors, Inc. v. Frescomar Corporation, et al., G.R. No. 226445, 2024.
Scenario B (tech product integration): A local system integrator uses an imported component and is sued for inducement or contributory infringement. The defense may argue there is no direct infringement, and therefore no indirect infringement, following Tuna Processors, Inc. v. Frescomar Corporation, et al., G.R. No. 226445, 2024, and contest whether the component is especially adapted for infringement and not suitable for substantial non-infringing use (R.A. No. 8293, Section 76.6).
Scenario C (process patent dispute): A local manufacturer is alleged to have used a patented process. The case will often turn on whether the accused process performs each claimed step (or its equivalent) and whether the patentee’s equivalence theory improperly deletes a step, consistent with Phillips Seafood Philippines Corporation v. Tuna Processors, Inc., G.R. No. 214148, 2023.
Final observations and recommendations
1) Start with the claims, not the product label. Early claim construction and an element-by-element comparison frequently determine litigation direction, consistent with Phillips Seafood Philippines Corporation v. Tuna Processors, Inc., G.R. No. 214148, 2023.
2) Treat indirect infringement as dependent on direct infringement. When sued as a distributor, supplier, or integrator, assess whether the complaint can first establish direct infringement, consistent with Tuna Processors, Inc. v. Frescomar Corporation, et al., G.R. No. 226445, 2024.
3) Demand technical proof for any doctrine-of-equivalents theory. Courts require meaningful proof of substantially the same function/way/result and do not allow equivalence to erase a material claim element, per Smith Kline Beckman Corporation v. Court of Appeals, et al., G.R. No. 126627, 2003 and Phillips Seafood Philippines Corporation v. Tuna Processors, Inc., G.R. No. 214148, 2023.
4) Evaluate remedy exposure early. Consider not only damages but also injunction risk and potential destruction/disposal orders under R.A. No. 8293, Section 76.2 to 76.5, which may affect inventory, contracts, and ongoing operations.
About Nicolas and De Vega Law Offices
Nicolas and de Vega Law Offices is a full-service law firm in the Philippines. You may visit us at the 16th Flr., Suite 1607 AIC Burgundy Empire Tower, ADB Ave., Ortigas Center, 1605 Pasig City, Metro Manila, Philippines. You may also call us at +632 84706126, +632 84706130, +632 84016392 or e-mail us at [email protected]. Visit our website https://ndvlaw.com.
